Your browser doesn't support javascript.
loading
T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.
Ekeruche-Makinde, Julia; Clement, Mathew; Cole, David K; Edwards, Emily S J; Ladell, Kristin; Miles, John J; Matthews, Katherine K; Fuller, Anna; Lloyd, Katy A; Madura, Florian; Dolton, Garry M; Pentier, Johanne; Lissina, Anna; Gostick, Emma; Baxter, Tiffany K; Baker, Brian M; Rizkallah, Pierre J; Price, David A; Wooldridge, Linda; Sewell, Andrew K.
Afiliación
  • Ekeruche-Makinde J; Institute of Infection and Immunity, Cardiff University School of Medicine, Henry Wellcome Building, Heath Park, Cardiff CF14 4XN, Wales, United Kingdom.
J Biol Chem ; 287(44): 37269-81, 2012 Oct 26.
Article en En | MEDLINE | ID: mdl-22952231
ABSTRACT
Altered peptide antigens that enhance T-cell immunogenicity have been used to improve peptide-based vaccination for a range of diseases. Although this strategy can prime T-cell responses of greater magnitude, the efficacy of constituent T-cell clonotypes within the primed population can be poor. To overcome this limitation, we isolated a CD8(+) T-cell clone (MEL5) with an enhanced ability to recognize the HLA A*0201-Melan A(27-35) (HLA A*0201-AAGIGILTV) antigen expressed on the surface of malignant melanoma cells. We used combinatorial peptide library screening to design an optimal peptide sequence that enhanced functional activation of the MEL5 clone, but not other CD8(+) T-cell clones that recognized HLA A*0201-AAGIGILTV poorly. Structural analysis revealed the potential for new contacts between the MEL5 T-cell receptor and the optimized peptide. Furthermore, the optimized peptide was able to prime CD8(+) T-cell populations in peripheral blood mononuclear cell isolates from multiple HLA A*0201(+) individuals that were capable of efficient HLA A*0201(+) melanoma cell destruction. This proof-of-concept study demonstrates that it is possible to design altered peptide antigens for the selection of superior T-cell clonotypes with enhanced antigen recognition properties.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Antígeno HLA-A2 / Linfocitos T CD8-positivos / Antígeno MART-1 / Antígenos de Neoplasias Límite: Humans Idioma: En Revista: J Biol Chem Año: 2012 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Receptores de Antígenos de Linfocitos T / Antígeno HLA-A2 / Linfocitos T CD8-positivos / Antígeno MART-1 / Antígenos de Neoplasias Límite: Humans Idioma: En Revista: J Biol Chem Año: 2012 Tipo del documento: Article País de afiliación: Reino Unido